Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
Protagonist Therapeutics (PTGX) Ownership - Who Owns Protagonist Therapeutics?
561 Followers
Protagonist Therapeutics (PTGX) Ownership Overview
5.63% Insiders
13.87% Mutual Funds
71.21% Other Institutional Investors
9.29% Public Companies and
Individual Investors
The ownership structure of Protagonist Therapeutics (PTGX) stock is a mix of institutional, retail and individual investors. Approximately 85.08% of the company’s stock is owned by Institutional Investors, 5.63% is owned by Insiders and 9.29% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Mar 11, 2024 | Harold Selick Director | Bought | $12266 |
| Mar 01, 2024 | Asif Ali Cfo | Sold | $764365 |
| Jan 04, 2024 | Sold | $30012 | |
| Apr 11, 2023 | Harold Selick Director | Bought | $5391 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2023 | Bought | $4555938 | |
| Dec 31, 2023 | Sold | $8788151 | |
| Dec 31, 2023 | Bought | $131490479 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 5,734,430 | Institution | 9.84% | 165,897,060 | |
| 2,982,367 | Institution | 5.12% | 86,279,877 | |
| 2,548,604 | Institution | 4.37% | 73,731,114 | |
| 2,543,244 | Institution | 4.36% | 73,576,049 | |
| 2,406,754 | Institution | 4.13% | 69,627,393 | |
| 2,032,552 | Institution | 3.49% | 58,801,729 | |
| 616,523 | Institution | 1.06% | 17,836,010 | |
| 589,955 | Institution | 1.01% | 17,067,398 | |
| 567,304 | Institution | 0.97% | 16,412,105 | |
| 484,854 | Institution | 0.83% | 14,026,826 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,543,244 | Institution | 4.36% | 73,576,049 | |
| 616,523 | Institution | 1.06% | 17,836,010 | |
| 589,955 | Institution | 1.01% | 17,067,398 | |
| 567,304 | Institution | 0.97% | 16,412,105 | |
| 484,854 | Institution | 0.83% | 14,026,826 | |
| 425,800 | Institution | 0.73% | 12,318,394 | |
| 422,313 | Institution | 0.72% | 12,217,515 | |
| 350,000 | Institution | 0.60% | 10,125,500 | |
| 277,431 | Institution | 0.48% | 8,026,079 | |
| 227,860 | Institution | 0.39% | 6,591,990 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 1,967,821 | Institution | 3.38% | 56,043,542 | |
| 1,700,416 | Institution | 2.92% | 51,658,638 | |
| 1,393,818 | Institution | 2.39% | 40,323,155 | |
| 848,210 | Institution | 1.46% | 25,768,620 | |
| 793,806 | Institution | 1.36% | 22,226,568 | |
| 793,806 | Institution | 1.36% | 22,226,568 | |
| 793,806 | Institution | 1.36% | 22,226,568 | |
| 412,094 | Institution | 0.71% | 11,921,879 | |
| 311,665 | Institution | 0.53% | 9,016,468 | |
| 269,646 | Institution | 0.46% | 7,679,518 |
FAQ
Who Owns Protagonist Therapeutics (PTGX)?
According to the latest TipRanks data, approximately 71.21% of the company's stock is held by institutional investors, 5.63% is held by insiders, and 9.29% is held by retail investors.
What percentage of Protagonist Therapeutics (PTGX) stock is held by institutional investors?
According to the latest TipRanks data, approximately 71.21% of Protagonist Therapeutics (PTGX) stock is held by institutional investors.
What percentage of Protagonist Therapeutics (PTGX) stock is held by retail investors?
According to the latest TipRanks data, approximately 9.29% of Protagonist Therapeutics (PTGX) stock is held by retail investors.
Who owns the most shares of Protagonist Therapeutics (PTGX)?
Andrew J.M. Spokes owns the most shares of Protagonist Therapeutics (PTGX).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.